3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
12
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
35
Recurrence
27
Multiple Myeloma
27
Leukemia, Lymphocytic, Chronic, B-Cell
27
Lymphoma, Non-Hodgkin
25
Lymphoma
20
Neoplasms
16
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma, B-Cell
15
Lymphoma, Follicular
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Mantle-Cell
13
Leukemia
13
Carcinoma, Non-Small-Cell Lung
13
Stomach Neoplasms
11
Ovarian Neoplasms
9
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
7
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Myelodysplastic Syndromes
6
Melanoma
6
Lymphoma, B-Cell, Marginal Zone
6
Breast Neoplasms
6
Liposarcoma, Myxoid
5
Colorectal Neoplasms
5
Burkitt Lymphoma
5
Interventions
blinatumomab
5
midostaurin
2
Azacitidine
2
venetoclax
1
tisagenlecleucel
1
siremadlin
1
sabatolimab
1
pulrodemstat besilate
1
posaconazole
1
fludarabine phosphate
1
fludarabine
1
Zoledronic Acid
1
Vitamin D
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Midazolam
1
Idarubicin
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Calcium
1
CD3 Complex
1
Anthracyclines
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasm, Residual
×
fludarabine
×
Clear all
NCT06500273
2026-06-02
ALPHA3
Allogene Therapeutics
Phase 2
Recruiting
250 enrolled